Literature DB >> 14872435

Thromboelastography and recombinant factor VIIa-hemophilia and beyond.

B Sørensen1, J Ingerslev.   

Abstract

Thromboelastography (TEG), which records the continuous profiles of whole blood (WB) coagulation, can be used to evaluate the effects of hemostatic agents, such as recombinant factor VII (rFVIIa). Our group has developed a revised TEG model, involving activation with minute amounts of tissue factor and subsequent signal processing, and has used this method to evaluate the effects of rFVIIa both in patients with hemophilia and in those receiving vitamin K antagonist (VKA) thromboprophylaxis. We review the early results of our investigations, which suggest that, in clinical situations where rFVIIa has shown benefit, the changes in the profiles obtained by TEG recording appear to correlate with the clinical outcome.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 14872435     DOI： 10.1053/j.seminhematol.2003.11.024

Source DB:  PubMed          Journal:  Semin Hematol        ISSN： 0037-1963            Impact factor:   3.851


  9 in total

Review 1.  Global coagulation assays: a clinical perspective.

Authors:  Ayesha Zia; Sarah H O'Brien
Journal:  J Thromb Thrombolysis       Date:  2015-01       Impact factor: 2.300

Review 2.  Dose titration of recombinant factor VIIa using thromboelastograph monitoring in a child with hemophilia and high titer inhibitors to factor VIII: a case report and brief review.

Authors:  Cody C Trowbridge; Alfred H Stammers; Nancy Ciccarelli; Myra Klayman
Journal:  J Extra Corpor Technol       Date:  2006-09

Review 3.  Resuscitation and transfusion principles for traumatic hemorrhagic shock.

Authors:  Philip C Spinella; John B Holcomb
Journal:  Blood Rev       Date:  2009-08-19       Impact factor: 8.250

4.  Monitoring rFVIII prophylaxis dosing using global haemostasis assays.

Authors:  M A Al Hawaj; E J Martin; J Venitz; J C Barrett; J G Kuhn; M E Nolte; D F Brophy
Journal:  Haemophilia       Date:  2013-03-19       Impact factor: 4.287

Review 5.  Mechanistic implications for the use and monitoring of recombinant activated factor VII in trauma.

Authors:  Anthony E Pusateri; Myung S Park
Journal:  Crit Care       Date:  2005-10-07       Impact factor: 9.097

Review 6.  Clinical experiences and current evidence for therapeutic recombinant factor VIIa treatment in nontrauma settings.

Authors:  R Michael Grounds; Charles Bolan
Journal:  Crit Care       Date:  2005-10-07       Impact factor: 9.097

7.  An in vitro evaluation of standard rotational thromboelastography in monitoring of effects of recombinant factor VIIa on coagulopathy induced by hydroxy ethyl starch.

Authors:  Martin Engström; Peter Reinstrup; Ulf Schött
Journal:  BMC Blood Disord       Date:  2005-02-15

8.  Thromboelastography and thrombin generation assessments for pediatric severe hemophilia A patients are highly variable and not predictive of clinical phenotypes.

Authors:  Natalie Mathews; Fred G Pluthero; Margaret L Rand; Ann Marie Stain; Manuel Carcao; Victor S Blanchette; Walter H A Kahr
Journal:  Res Pract Thromb Haemost       Date:  2022-09-26

9.  Thromboelastometry assessment of hemostatic properties in various murine models with coagulopathy and the effect of factor VIII therapeutics.

Authors:  Jocelyn A Schroeder; Erin A Kuether; Juan Fang; Weiqing Jing; Hartmut Weiler; David A Wilcox; Robert R Montgomery; Qizhen Shi
Journal:  J Thromb Haemost       Date:  2021-07-23       Impact factor: 16.036
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.